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Whole-exome sequencing provides a cost-effective means to sequence protein coding regions within the genome,
which are significantly enriched for etiological variants. We describe a panel of single nucleotide polymorphisms
(SNPs) to facilitate the validation of data provenance in whole-exome sequencing studies. This is particularly
significant where multiple processing steps necessitate transfer of sample custody between clinical, laboratory and
bioinformatics facilities. SNPs captured by all commonly used exome enrichment kits were identified, and filtered
for possible confounding properties. The optimised panel provides a simple, yet powerful, method for the
assignment of intrinsic, highly discriminatory identifiers to genetic samples.Background
Whole-exome sequencing (WES) is presently one of the
most efficient means of identifying aetiological genetic mu-
tations [1], minimising some of the challenges associated
with whole-genome sequencing, such as high cost and data
processing burden, analysis and interpretation. In WES,
protein-coding regions of the genome are targeted and
enriched via specific hybridisation of genomic fragments
with complementary oligonucleotides, or ‘baits’. These
targeted regions are then sequenced using high throughput
next-generation sequencing (NGS) technologies [2].
The high start-up investment required for in-house
WES is currently prohibitive to many groups so sample
preparation and/or sequencing is commonly outsourced.
This transference of sample custody, combined with the
complex sample preparation workflow, makes sample
mix-ups possible, and difficult to detect. In both clinical
and research contexts, ensuring provenance of data is es-
sential to allow the accurate assignment of clinical details
to sequence data. It is possible that samples may be mis-
identified at any stage of the analytical process, both
in vitro and in silico. Therefore, sample tracking must be
contiguous throughout both data generation and analysis.
Consequent to sample mix-ups in a research setting,
erroneous data and sample matching may result in a loss* Correspondence: s.ennis@soton.ac.uk
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reproduction in any medium, provided the orof power for identification of causal variants [3]. In a
clinical setting, this may lead to delayed or inaccurate
reporting of results to patients. Whilst good practice in
the handling of samples and increased laboratory auto-
mation minimises potential for error, additional check-
points are still required to support quality control [4]. A
method for post hoc confirmation of sample identity is
therefore highly desirable.
Genetic sample identification methods have an advan-
tage over alternative sample management systems in that
the genetic ‘label’ is intrinsic to the biological sample it-
self, removing the possibility of manual labelling errors.
Single nucleotide polymorphisms (SNPs) are increasingly
utilised for DNA-based identification of human samples,
with several benefits compared to standard forensic
methods [5-7]. Existing SNP panels for human forensic
identification and commercial SNP panels for sample
identification, such as the iPLEX Sample ID Plus panel
(Sequenom, San Diego, CA, USA), utilise pan-genome
SNPs, the majority of which are non-exonic, and are
therefore not useful for WES studies, as the majority of
markers will not lie within the enriched regions of the
genome. In addition to existing SNP panels, short tan-
dem repeat markers can be used for genetic sample
tracking. However, again, markers applied are frequently
outside exomic regions and, if captured, will be prone to
erroneous NGS genotyping using standard pipelines due
to the repetitive nature of the markers [8].
Several methods for genetic tracking of human bio-
logical samples have been previously described, some ofl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scriptome microarray studies [3,9,10]. Although software
for the validation of NGS (including WES) sample iden-
tity, such as verifyBamID, exist [11], for the detection of
sample misidentifications external array-based genotypes
of the samples are required, without which only contam-
ination of the samples can be assessed.
Here we describe an optimised panel of SNPs for which
WES data are typically informative, the genotypic profile of
which can be utilised to extract intrinsic identifiers from
human genomic DNA. These SNP profiles have high dis-
criminatory power, even in large datasets. The profile de-
rived from this panel can be compared to an independently
genotyped profile for the same individual, allowing accurate
validation of data and sample pairings, at a modest cost per
sample.
Methods
Candidate identification and panel selection
Regions of overlap between three current commonly
used whole-exome enrichment kits, (namely Agilent
SureSelect Human All Exon V4, Illumina TruSeq
Exome Enrichment and Nimblegen SeqCap EZ Human
Exome Library V3.0 kits), and common SNPs (dbSNP
137, [12]) were established using BEDTools [13]. SNPs
were further filtered for inclusion based upon their
presence in genes targeted by the Illumina TruSight
Exome kit, which targets only genes of clinical interest.
Primary candidate selection criteria required SNPs to:
1) represent bi-allelic substitutions, excluding substitu-
tions of complementary bases, that is, A↔T and G↔C
transversions; 2) be technically amenable to both accur-
ate WES and orthogonal genotyping, that is, not present
in large-scale genomic repeats [14], or homopolymeric
tracts of ≥5 bp, GC content for the flanking 250 bp was
restricted to a range of between 40% and 55% and no
other variant within 50 bp with an alternative-allele fre-
quency (AF) ≥0.01 was permitted; 3) conform to desir-
able phase 3 HapMap AFs across several populations,
explicitly AFs of between 0.2 and 0.8 in: CEPH (Utah
residents with ancestry from northern and western
Europe; CEU), Japanese in Tokyo, Japan (JPT), Han
Chinese in Beijing, China (CHB) and Yoruba in Ibidan,
Nigeria (YRI) [15] and; 4) not alter the primary sequence
of the encoded protein or have an associated Online
Mendelian Inheritance in Man (OMIM) record [16].
Following primary candidate identification steps,
SNPs were further optimised by the following require-
ments: 1) be located at least 10 bp from exon boundar-
ies; 2) not be situated in regions with a high sequence
similarity to non-target regions, that is, no non-target
BLAT score >100 [17], as this could result in non-
specific genotyping; and 4) be outside of linkage dis-
equilibrium with all other selected SNPs.Finally, SNPs were prioritised for inclusion in the
panel by proximity of the AFs to 0.5, across HapMap
populations, in order to maximise discriminatory power.
SNP coverage in whole-exome sequencing data
A set of 91 in-house exome samples was evaluated for
depth of sequence coverage for the candidate SNPs. Exome
capture was performed using Agilent SureSelect Human
All Exon V3 (n = 22) and V4 (n = 55), Illumina TruSeq
Exome Enrichment (n = 9) and Nimblegen SeqCap EZ
Human Exome Library V3.0 (n = 5). Exome enrichment,
sequencing and in silico analysis of samples was performed
as previously described [18,19].
Optimised panel validation
The power of sample resolution for the panel was vali-
dated using data from phase 1 of the 1000 Genomes
Project (n = 1,092) [20] and the UK10K project
(n = 2,688; 2,432 of which are whole-genome data) [21].
Genotypes were extracted from data using custom
scripts and Tabix [22]. Quantification of mismatches be-
tween samples was performed using MEGA5 [23].
Simulated datasets were generated by taking individual
population AFs for each SNP as input and generating ran-
dom SNP profiles in accordance with Hardy-Weinberg
equilibrium based upon this; the randomisation of each
SNP was independent of all other SNPs. We then quanti-
fied the rate of non-unique profiles per simulated dataset.
We performed 20,000 independent replicates of dataset
generation in all cases.
Panel application
We applied the panel to a batch of 48 samples exome se-
quenced by an external service provider, for which or-
thogonal genotypes were obtained concurrently through
an independent genotyping provider using KASP geno-
typing (LGC Genomics, Hoddeston, UK). Following plat-
ing of DNA samples for dispatch, a replicate plate was
made directly from the primary plate, to be dispatched
for the orthogonal genotyping. Genotypes derived from
exome data and orthogonal genotyping assays were
compared using PLINK [24] and custom scripts.
Ethics
This study was approved by the Southampton and South
West Hampshire Research Ethics Committee (09/H0504/
125). Informed consent was obtained for all participants.
Results
In total, 26.2 Mbp of genome sequence was found
to overlap all three commonly applied whole-
exome capture kits, containing 9,493 common SNPs
(Figure 1A,B). Of these, 1,662 SNPs are additionally



































Technically amenable HapMap3 frequenciesC
Figure 1 Venn diagrams showing commonality of targeting between capture kits (A,B) and properties of encompassed SNPs (C).
Overlap between exome capture kits is presented in Mbp (A) and number of SNPs with an AF ≥0.3 (B). Agilent - SureSelect Human All Exon V4;
Illumina - TruSeq Exome Enrichment; Nimblegen - SeqCap EZ Human Exome Library V3.0. For a subset of SNPs present in both the intersection of the
three kits shown, and the Illumina TruSight Exome kit, a breakdown of fulfilment of the four classes of candidate filtering criteria is shown (C) (see the
main text for details of filtering criteria); 117 SNPs exhibited all desired characteristic; 74 SNPs exhibited none of the desired characteristics.
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criteria, 117 candidate SNPs were identified (Figure 1C;
Additional file 1), from which the optimised panel of 24
SNPs was selected (Table 1). Within the set of 91 in-house
exome samples, all 24 SNPs were sequenced at sufficientread-depth for accurate genotype calling, across all cap-
ture kits.
The 24 biallelic SNPs afford 48 points of allelic
comparison. Testing the optimised panel in the 1000
Genomes Project data (n = 1,092) [20], an average of
Table 1 Optimised panel of identifying SNPs
Chromosome Positiona dbSNP rsID Gene Alleles HapMap 3 AF
CEU CHB JPT YRI
1 179520506 rs1410592 NPHS2 A/C 0.59 0.62 0.54 0.53
1 67861520 rs2229546 IL12RB2 A/G 0.64 0.36 0.44 0.58
2 169789016 rs497692 ABCB11 A/Gb 0.55 0.65 0.51 0.22
2 227896976 rs10203363 COL4A4 C/T 0.46 0.44 0.36 0.57
3 4403767 rs2819561 SUMF1 A/Gb 0.56 0.73 0.73 0.72
4 5749904 rs4688963 EVC A/Gb 0.33 0.65 0.67 0.52
5 82834630 rs309557 VCAN A/Gb 0.49 0.34 0.52 0.50
6 146755140 rs2942 GRM1 C/T 0.54 0.49 0.55 0.47
7 48450157 rs17548783 ABCA13 C/T 0.46 0.72 0.53 0.48
8 94935937 rs4735258 PDP1 C/T 0.40 0.64 0.66 0.46
9 100190780 rs1381532 TDRD7 A/Gb 0.48 0.59 0.50 0.58
10 100219314 rs10883099 HPSE2 A/G 0.52 0.52 0.53 0.62
11 16133413 rs4617548 SOX6 C/T 0.52 0.65 0.61 0.51
12 993930 rs7300444 WNK1 A/G 0.46 0.55 0.48 0.28
13 39433606 rs9532292 FREM2 A/G 0.29 0.41 0.44 0.54
14 50769717 rs2297995 L2HGDH A/G 0.55 0.65 0.67 0.59
15 34528948 rs4577050 SLC12A6 C/T 0.68 0.75 0.63 0.32
16 70303580 rs2070203 AARS A/Gb 0.53 0.28 0.51 0.49
17 71197748 rs1037256 COG1 C/T 0.50 0.67 0.65 0.56
18 21413869 rs9962023 LAMA3 A/G 0.67 0.81c 0.75 0.51
19 10267077 rs2228611 DNMT1 C/Tb 0.47 0.73 0.56 0.48
20 6100088 rs10373 FERMT1 G/Tb 0.54 0.31 0.35 0.58
21 44323590 rs4148973 NDUFV3 C/T 0.65 0.33 0.38 0.73
22 21141300 rs4675 SERPIND1 A/C 0.46 0.62 0.51 0.57
aPosition as defined in genome reference assembly GRCh37 (hg19).
bSNP is defined on the negative strand.
cAF marginally outside target range for candidate selection. Selected due to paucity of candidates on chromosome 18.
Table 2 Profile collisions per simulated dataset of 10,000
individuals with various population AFs
AF source Average collisions per dataset (±SD)






Theoretical perfecta 0.0031 (0.056)
aAll 24 SNPs assigned an AF of 0.5, which will give the most even trifurcation
per SNP, and thus discriminatory power. SD, standard deviation.
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tween all pairwise combinations was observed, with a
range of 3 to 34. As such, there will be, on average, 18
differential alleles between any two samples, enabling
discrimination.
On addition of the UK10K data (n = 2,688) to the
1000 Genomes Project data (ncombined = 3,780), there
remained an average of 17.8 allele mismatches across
the profiles. Eighteen UK10K sample pairs produced
duplicate profiles. On investigation of these pairs, they
were found to share >98% genotypic concordance across
an extended panel of 1,662 SNPs in all cases, compared
to an average of 42%, with a range of 27 to 77%, for
all sample pairs with unique SNP profiles (Additional
file 2). As such, these pairs represent extreme outliers,
and are derived from genetically identical biological
samples, either from the same individual or monozy-
gotic twins, and were therefore excluded from the mis-
match average.Simulated data
The discriminatory power of the panel was evaluated
by dataset simulation. We simulated datasets of 10,000
individuals, that conformed to AF distributions for investi-
gated HapMap populations (CEU, CHB, JPT and YRI),
Figure 2 Relationship between size of simulated datasets and the occurrence of non-unique profiles. Thirteen 1000 Genomes Project
populations were simulated [20]. Datasets were simulated as described in Methods. With increasing dataset size, the probability of repeat profiles
increases. Only populations with a sample size of >50 individuals in the dataset were simulated. Additional populations are Americans of African
ancestry in Southwest USA (ASW), Columbians from Medellin, Colombia (CLM), Finnish in Finland (FIN), British in England and Scotland (GBR),
Luhya in Webuye, Kenya (LWK), Mexican ancestry from Los Angeles, USA (MXL), Puerto Ricans from Puerto Rico (PUR) and Toscany in Italia (TSI).
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hypothetical perfect allele distribution (AF = 0.5 for all
SNPs) (Table 2). In all simulated populations, <2.5% of
simulated datasets of 10,000 contained any repeat SNP
profiles (henceforth termed ‘collisions’). This translates ap-
proximately into less than 1 in every 40 independent
datasets of 10,000 individuals containing a single matching
pair of profiles.
The effect of dataset size on the frequency of collisions
was investigated for populations present in 1000 Genomes
Project phase 1 data [20]. An exponential increase in the
frequency of collisions was observed with increasing
dataset size, though the panel continued to have high
power for the discrimination of samples. For instance,




















































1 Exome A A G A C C C T G G T T T C G A T C C T A A A
Geno N N G A C C C T G G T T T C G A T C C T A A A
2 Exome C A A A C C C T A G T T T C G A T C C C A A G
Geno C A G A T C C T G G T T T C A A C C C C G G A
3 Exome C A G A T C C T G G T T T C A A C C C C G G A
Geno C A A A C C C T A G T T T C G A T C C C A A G
4 Exome C A A A T T C T G G T T T C G A T C C T A A G
Geno C A A A T T C T G G T T T C G A T C C T A A G
Figure 3 Exome derived and orthogonal genotypes (Geno) for four sa
Informative markers for the resolution of this switch are highlighted in yellosamples, (the worst performing 1000 Genomes population
evaluated, due to the AF distribution for SNPs within this
panel), we would expect the dataset to contain, on average,
a single duplicate SNP profile (Figure 2). In addition, total
SNP absence - for example, through technical failure of
orthogonal genotyping - was modelled. For each SNP that
entirely failed to provide data, a less than three-fold drop
in discriminatory power was observed in all cases (data
not shown). This suggests that our approach is robust
against technical failure.
Application of the SNP panel to our batch of 48 samples
revealed a discrepancy between exome and orthogonal
genotypes for two samples dispatched in adjacent wells,
suggesting a reciprocal transposition (Figure 3). The
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mples, showing a sample-switch between samples 2 and 3.
w.
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gosity to confirm sample gender. In addition to the identi-
fication of the switch, the panel allowed for expeditious
resolution of the error, permitting the continued use of
the data in downstream analyses.
Discussion
Validation of sample identity is essential in order to ensure
data integrity and validity of conclusions drawn from data.
We have described a powerful tool for the identification
and validation of data provenance throughout the work-
flow of WES data collection and analysis. The power of
discrimination, that is, the precision with which samples
can be uniquely identifiable, is sufficient and robust for
most projects on the current scale of up to 10,000 sam-
ples, with inbuilt redundancy of SNPs to protect against
technical failures. In WES, the exome enrichment process
provides the limiting step for the availability of data on
SNPs for use in sample identification. As such, this panel
will also be of utility for whole-genome sequencing data,
where there is no such limitation on SNP coverage. This
will be beneficial where there are mixed datasets of both
whole-genome sequence and WES data.
NGS is now developing as the diagnostic methodology of
choice across a range of applications, including mutation
scanning in targeted gene panels and WES for congenital
disorders, as well as high depth analysis for tumour profil-
ing. Whilst the service model for delivery of these tests is
not fully resolved at this stage, there will certainly be eco-
nomic arguments for centralising certain tests. This will
have the effect of increasing the throughput requirements
as well as physically moving samples between labs. Both of
these factors will increase the opportunity for sample
misidentification.
Even for testing within a single lab, the use of inherent
sample and data identification methods, as described in
this study, seems a robust approach to fulfil the regulatory
requirement for providing a full audit trail and ensuring
data provenance [26,27]. The SNP panel presented here is
immediately usable across all commonly used exome cap-
ture kits, and would be equally applicable to any gene
panel by incorporating, or ‘spiking’, the SNP regions into
the custom capture kit at the design stage. Where it can
be shown that there are no expected repeat profiles (that
is, no paired samples from the same individual are being
analysed), it may even be beneficial from a process per-
spective to use the SNP profile as the primary method for
sample tracking.
The discriminatory power of the panel may be re-
duced for various reasons, such as geographically local-
ised variation in AFs, and degradation of DNA samples,
resulting in incomplete data. We have shown our panel
to have a high discriminatory power across a diverse
range of populations. Additionally, the discriminatorypower will be marginally reduced where many relatives
are sequenced. In the case of highly consanguineous
families, sample tracking methods such as barcoding
will afford optimal certainty in these particular cases.
Should concerns over insufficient discriminatory power
arise, additional SNPs may be added to the panel from
the existing list of candidates (Additional file 1), also
allowing the tailoring of an enhanced panel to the popu-
lation(s) of interest, should this be desired. Neverthe-
less, we have demonstrated our panel to be sufficiently
robust to withstand power reductions without loss of
utility for most purposes.
We have also presented a recent case in which use of
this panel has allowed us to identify, confirm, and resolve
a sample switch, highlighting the importance of using such
a tool. Monetary cost will vary with the technology used
for orthogonal genotyping and sample throughput. We
have intentionally designed the panel to be platform non-
specific, allowing for the establishment of in-house assays
using preferred genotyping methodology or outsourced
where required. Our own chosen methodology costs ap-
proximately £5 GBP per sample, representing a small frac-
tion of the cost of exome data generation.
Conclusions
The size of held NGS datasets continues to increase, with
the UK Government recently committing to the sequen-
cing of 100,000 samples as part of healthcare provisions
[28]. As such, the demand for the development of effective
tools for bioinformatic analysis, data compression, muta-
tion effect prediction and quality control is high. We have
described a panel of SNPs for the discrimination of human
biological samples on the basis of data intrinsic to WES
data derived from samples processed using common cap-
ture kits. We recommend the routine use of this panel to
maintain data integrity and protect sample provenance.Additional files
Additional file 1: List of all candidate SNPs with evaluated
properties.
Additional file 2: Distribution of pairwise genotype concordance
between samples. Pairs resulting in duplicate SNP profiles (n = 18) and
pairs between samples with unique SNP profiles (n = 7,142,293) within
the combined dataset of 3,780 samples are shown. Concordance across
the 1,662 SNPs detailed in Figure 1C was evaluated. All pairs resulting in
duplicate profiles have >98% concordance, well separated from the
distribution of samples with unique profiles. Note the logarithmic scale.Abbreviations
AF: alternative-allele frequency; bp: base pair; CEU: CEPH (Utah residents with
ancestry from northern and western Europe); CHB: Han Chinese in Beijing,
China; CHS: Southern Han Chinese; JPT: Japanese in Tokyo, Japan;
Mbp: megabase pair; NGS: next-generation sequencing; SNP: single
nucleotide polymorphism; WES: whole-exome sequencing; YRI: Yoruba in
Ibidan, Nigeria.
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